0      0


CT-1.5-SY32 - Oral Semaglutide for Treatment of Obesity and Type 2 Diabetes—Results from OASIS 1 and PIONEER PLUS Trials (Includes Livestream)


‐ Jun 25, 2023 6:00pm


Speaker(s):

You must be logged in and own this session in order to post comments.